Global Personalized Medicine Partnering Deal Trends, Players, Financials and Forecasts Report 2012-2018 - ResearchAndMarkets.com

DUBLIN--()--The "Global Personalized Medicine Partnering 2012-2018: Deal trends, players, financials and forecasts" report has been added to ResearchAndMarkets.com's offering.

The Global Personalized Medicine Partnering 2012-2018 report provides a comprehensive understanding and unprecedented access to the personalized medicine partnering deals and agreements entered into by the worlds leading healthcare companies.

This report provides details of the latest Personalized Medicine agreements announced in the life sciences since 2012.

The report takes the reader through a comprehensive review Personalized Medicine deal trends, key players, top deal values, as well as deal financials, allowing the understanding of how, why and under what terms, companies are entering Personalized Medicine partnering deals.

The report presents financial deal term values for Personalized Medicine deals, listing by headline value, upfront payments, milestone payments and royalties, enabling readers to analyse and benchmark the financial value of deals.

The middle section of the report explores the leading dealmakers in the Personalized Medicine partnering field; both the leading deal values and most active Personalized Medicine dealmaker companies are reported allowing the reader to see who is succeeding in this dynamic dealmaking market.

One of the key highlights of the report is that over 1,370 online deal records of actual Personalized Medicine deals, as disclosed by the deal parties, are included towards the end of the report in a directory format - by company A-Z, stage of development, deal type, therapy focus, and technology type - that is easy to reference. Each deal record in the report links via Weblink to an online version of the deal.

In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners. Whilst many companies will be seeking details of the payment clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.

Key benefits

  • In-depth understanding of Personalized Medicine deal trends since 2012
  • Access to headline, upfront, milestone and royalty data
  • Analysis of the structure of Personalized Medicine agreements with numerous real life case studies
  • Detailed access to actual Personalized Medicine contracts entered into by leading biopharma companies
  • Identify most active Personalized Medicine dealmakers since 2012
  • Insight into terms included in a Personalized Medicine partnering agreement, with real world examples
  • Understand the key deal terms companies have agreed in previous deals
  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Report scope

Personalized Medicine Partnering Terms and Agreements includes:

  • Trends in Personalized Medicine dealmaking in the biopharma industry since 2012
  • Analysis of Personalized Medicine deal structure
  • Access to headline, upfront, milestone and royalty data
  • Case studies of real-life Personalized Medicine deals
  • Access to Personalized Medicine contract documents
  • Leading Personalized Medicine deals by value since 2012
  • Most active Personalized Medicine dealmakers since 2012

Available deals are listed by:

  • Company A-Z
  • Headline value
  • Stage of development at signing
  • Deal component type
  • Specific therapy target
  • Technology type

Key Topics Covered:

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in Personalized Medicine dealmaking

Chapter 3 - Leading Personalized Medicine deals

Chapter 4 - Most active Personalized Medicine dealmakers

Chapter 5 - Personalized Medicine contracts dealmaking directory

Chapter 6 - Personalized Medicine dealmaking by technology type

Chapter 7 - Partnering resource center

For more information about this report visit https://www.researchandmarkets.com/research/3kzph3/global?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Genomics

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Genomics